Evgen has announced a partnering deal with Swiss biotech company Stalicla for the investigation of SFX-01 as a potential treatment of autism spectrum disorder (ASD) and other CNS disorders, monetising non-core indications for the drug. The deal could generate up to $160.5m in milestone payments in the ASD indication and double-digit royalties on end-market sales in all partnered indications for Evgen. Evgen retains global rights in all other indications. The upfront and near-term (c.<1 year) mil ....
10 Oct 2022
Evgen Pharma - Monetising non-core indications & lengthening cash runway
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - Monetising non-core indications & lengthening cash runway
Evgen Pharma Plc (EVG:LON) | 0.8 0 0.0% | Mkt Cap: 3.31m
- Published:
10 Oct 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
8
Evgen has announced a partnering deal with Swiss biotech company Stalicla for the investigation of SFX-01 as a potential treatment of autism spectrum disorder (ASD) and other CNS disorders, monetising non-core indications for the drug. The deal could generate up to $160.5m in milestone payments in the ASD indication and double-digit royalties on end-market sales in all partnered indications for Evgen. Evgen retains global rights in all other indications. The upfront and near-term (c.<1 year) mil ....